(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co’s Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer.
Opdivo, part of a new class of medicines designed to use the body’s own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma.
Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy, Yervoy, as an initial treatment for lung cancer.
The FDA is slated to decide in May whether to approve rival Merck & Co Inc’s combination of immunotherapy Keytruda and chemotherapy for first-line lung cancer.
Reporting By Deena Beasley; editing by Diane Craft